You are here: Industry Insights > Astellas Pharma

News List

PADCEV succeeds in confirmatory phase 3 trial in urothelial cancer pharmaceutical-business-review
September 23, 2020
Seattle Genetics and Astellas Pharma said that PADCEV (enfortumab vedotin-ejfv) met the primary endpoint of overall survival (OS) in a confirmatory phase 3 trial in previously treated locally advanced or metastatic urothelial cancer.
Astellas, iota Biosciences enter into collaborative R&D agreement biospectrumasia
September 17, 2019
Under this collaboration, Astellas and iota will jointly design detailed specifications of implantable medical devices and conduct preclinical studies for several diseases with high unmet medical needs.
NapaJen Pharma and Astellas Pharma Establish ResearchapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides pharmatimes
March 19, 2019
Ono Pharma, twoXAR Enter Drug Discovery Alliance.
Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals pharmaceutical-technology
December 24, 2018
Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.Astellas made an upfront payment of $164.6m and has agreed to...
Astellas Pharma Exec Shares His Best Life Science Career Advice biospace
December 26, 2017
MM&M recently profiled a number of pharmaceutical executives, including Walt Johnston,Astella Pharma U.S.’s general manager and senior vice president of its urology hospital business unit.
Astellas Discontinues ASP8273 Treatment and Closes Randomization for Clinical Study Protocol 8273-CL americanpharmaceuticalreview
May 12, 2017
Astellas Pharma announced the discontinuation of ASP8273 treatment arm in late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus erlotinib/gefitinib for the first-line treatment metastatic...